{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-193428","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2023-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.655584+00:00","generated_at":"2026-06-13T03:21:36.531081+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BMF-219 induces 2 complete responses in 5 AML patients with menin mutations in Phase I trial","bullets":["2 of 5 relapsed/refractory AML patients with menin-dependent mutations achieved CRs at Dose Level 4 (500mg or 125mg QD).","CRs observed within first two 28-day cycles; both patients continue on BMF-219 treatment.","No dose-limiting toxicities or QTc prolongation reported; generally well tolerated.","Dose Level 5 enrollment commenced to explore optimal biological dose.","Biomea plans to present additional data at an upcoming medical conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-193428","json":"https://secwatch.observer/filing/0001193125-23-193428.json","markdown":"https://secwatch.observer/filing/0001193125-23-193428.md","text":"https://secwatch.observer/filing/0001193125-23-193428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312523193428/0001193125-23-193428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312523193428/d434383d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T03:21:36.531081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}